2009年12月16日星期三

Protagen AG - Protagen closes new annular of costs to strengthen technology position for atypical diagnostics

Dortmund, Germany and New Jersey, USA, August 1, 2008: Protagen AG, a arch provider of GMP adjustable protein analytic services, protein bioinformatics, and protein biochips announces the closing of a new annular of financing. The basic will be acclimated to strengthen and aggrandize the company’s UNIarray® technology position and the development of atypical diagnostics. The basic aloft in this annular has appear from the absolute institutional investors, MIG AG, Munich, S-Venture Capital Dortmund GmbH, and Kreditanstalt für Wiederaufbau (KfW).

Background: UNIarray® is a different technology belvedere for the development of atypical affection based on adumbration specific autoantibody patterns in accommodating sera. These adumbration specific autoantibody patterns were already accurate to be present in several autoimmune diseases, but aswell in cancer, neurodegenerative disorders, and even in allegedly advantageous individuals. Therefore, the analytical and indication-specific assurance of autoantibody patterns will serve as a different base to abode ahead unmet analytic needs. In addition, UNIarray® serves as a belvedere for the development of artefact specific accompaniment affection and accommodating stratification for analytic studies. In-house analysis at Protagen is anon focused on atypical affection for prostate cancer, assorted sclerosis, rheumatoid arthritis, adolescent idiopathic arthritis, Morbus Parkinson, and Alzheimer’s.

At the aforementioned time Dr. Christoph Hüls (CEO) will leave Protagen for clandestine affidavit and will move to a new position in a ample biologic company. The Chairman of the Board of Protagen AG, Prof. Axel Kleemann, abjure the abandonment of Christoph Hüls and the end of a continued and artless cooperation. Dr. Stefan Müllner (CSO) will crop over the position as new CEO.

Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de

Media Enquiries
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
Fax: +49 (0) 69 6199 4249
E-Mail: info@holgerbengs.de

About Protagen AG
Protagen AG (www.protagen.de) is a arch provider of products, casework and software solutions for protein analysis with sites in Dortmund, Germany, and Chester, New Jersey, USA. Technology innovations of Protagen are UNIclone®, a patented belvedere for development and use of protein announcement libraries, and UNIchip®, a able and awful able ancestors of articles for the development of antibodies, as able-bodied as UNIarray®, a different technology abject for the development of new diagnostics.

没有评论:

发表评论